Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 3-mmc Compound
1. 3-mmc
2. 1246816-62-5
3. 2-(methylamino)-1-(3-methylphenyl)-1-propanone
4. 2-(methylamino)-1-(3-methylphenyl)propan-1-one
5. Unii-73q9qto1n4
6. 73q9qto1n4
7. 1-propanone, 2-(methylamino)-1-(3-methylphenyl)-
8. 3-methylmethcathinone (hydrochloride)
9. Mepedrone
10. 3-methylmethcathinone (3-mmc)
11. Schembl20472228
12. Qdnxsiywhygmcd-uhfffaoysa-n
13. Dtxsid401043421
14. Pd048123
15. Ft-0701142
16. 1-(3-methylphenyl)-2-(methylamino)-1-propanone
17. Q27266198
18. 1246911-86-3
| Molecular Weight | 177.24 g/mol |
|---|---|
| Molecular Formula | C11H15NO |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 29.1 |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 179 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinson's disease.
Lead Product(s): 3-Methylmethcathinone,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Lead Product(s) : 3-Methylmethcathinone,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Clearmind Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinson's di...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
August 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
